ACE and liver dysplastic nodule: Differences in the renal protective ability of ACE inhibitors and AT1R blockers (ARB) have been described in experimental DN, which were attributable to the capacity of ACE inhibitor, but not ARB, to prevent ACE-induced Ac-SDKP degradation (Nagai et al., 2014; Srivastava et al., 2020a; Srivastava et al., 2020b).